A daily low dose of aspirin could significantly reduce the risk of colorectal cancer returning in certain patients, according to a clinical trial published in the New England Journal of Medicine. The study, conducted by researchers at the Karolinska Institute and Karolinska University Hospital in Sweden, involved 626 participants with stages 1 to 3 colon or rectal cancer whose tumors carried specific genetic mutations.Why This Study MattersColorectal cancer affects about 2 million people worldwide every year, and between 30 to 40% of them experience a recurrence. Identifying low-cost, widely available treatments that can prevent relapse is critical in improving survival rates and easing the burden on healthcare systems.This trial is particularly significant because while earlier observatio

See Full Page